Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ascendis Pharma A/S    ASND

ASCENDIS PHARMA A/S (ASND)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/13/2018 06/14/2018 06/15/2018 06/18/2018 06/19/2018 Date
68.81(c) 67.07(c) 66.53(c) 66.6(c) 66.98(c) Last
98 749 161 525 142 657 91 509 249 459 Volume
-3.08% -2.53% -0.81% +0.11% +0.57% Change
More quotes
Financials (EUR)
Sales 2018 2,86 M
EBIT 2018 -147 M
Net income 2018 -159 M
Finance 2018 240 M
Yield 2018 -
Sales 2019 2,53 M
EBIT 2019 -154 M
Net income 2019 -185 M
Finance 2019 67,6 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 748x
EV / Sales2019 915x
Capitalization 2 380 M
More Financials
Company
Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates.Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market.The company was founded by Jan... 
More about the company
Surperformance© ratings of Ascendis Pharma A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on ASCENDIS PHARMA A/S
06/06Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon PTH as..
GL
06/01ASCENDIS PHARMA A/S : Reports First Quarter 2018 Financial Results
AQ
06/01ASCENDIS PHARMA A/S : Reports First Quarter 2018 Financial Results
AQ
05/30Ascendis Pharma A/S Reports First Quarter 2018 Financial Results
GL
05/25ASCENDIS PHARMA A/S : quaterly earnings release
05/16ASCENDIS PHARMA A/S : Announces First Quarter 2018 Financial Results and Busines..
AQ
05/14ASCENDIS PHARMA A/S : Announces Dosing of First Subjects in Phase 1 Trial of Tra..
AQ
05/11ASCENDIS PHARMA A/S : Announces Poster Presentation on TransCon PTH Phase 1 Tria..
AQ
05/10ASCENDIS PHARMA A/S : Wired News - Ascendis Pharma Dosed First Subjects in First..
AC
05/08Ascendis Pharma A/S Announces Dosing of First Subjects in Phase 1 Trial of Tr..
GL
More news
Sector news : Bio Therapeutic Drugs
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/12GSK says vaccine business president to leave by year-end
RE
06/06Drugmaker Lundbeck to settle U.S. charity probe for $52.6 million
RE
06/01Lilly, Incyte Get FDA OK for Lower-Dose Rheumatoid Arthritis Drug
DJ
05/30Gap in regulating biotech drug copies prompts WHO to step in
RE
More sector news : Bio Therapeutic Drugs
Latest Tweets
06/18MISSING: Scott Smith was last seen Sunday. He left in his green 1997 Ford Ran..
1
06/16$130,000.00 in Sales Expected for Ascendis Pharma A/S $ASND This Quarter  
06/15Working on cool new feature for 2H18 OI Report, industry sorted flows, here i..
6
06/15H.C. Wainwright Reiterates a Buy Rating on Ascendant Resources Inc $ASND  
06/10Ascendis Pharma A/S $ASND Downgraded by BidaskClub to “Buy”  
More tweets
Qtime:119
News from SeekingAlpha
06/16INSTITUTIONAL TOP IDEAS : Cormorant Asset Management 
06/12INSTITUTIONAL TOP IDEAS : EcoR1 Capital 
05/30Ascendis Pharma A/S (ASND) CEO Jan Mikkelsen on Q1 2018 Results - Earnings Ca.. 
05/30Ascendis Pharma  misses by $0.33, misses on revenue 
05/30Ascendis Pharma  misses by $0.33, misses on revenue 
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | ASND | US04351P1012 | 4-Traders
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 65,0 €
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Jan Møller Mikkelsen President, Chief Executive Officer & Director
Michael Wolff Jensen Chairman, SVP & General Counsel
Neil T. Ringdahl Chief Operating Officer
Scott T. Smith Chief Financial Officer & Senior Vice President
Harald Rau Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ASCENDIS PHARMA A/S66.08%2 767
GILEAD SCIENCES-1.97%91 317
VERTEX PHARMACEUTICALS3.44%39 504
REGENERON PHARMACEUTICALS-16.13%33 406
NEUROCRINE BIOSCIENCES, INC.31.87%9 198
GENMAB-6.67%9 197